Drug Profile
Research programme: anti-cd38 antibodies - ProMIS Neurosciences/Trellis Bioscience
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Amorfix Life Sciences; Trellis Bioscience
- Developer ProMIS Neurosciences; Trellis Bioscience
- Class Monoclonal antibodies
- Mechanism of Action CD38 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Haematological-malignancies in Canada (Parenteral)
- 28 Jul 2018 No recent reports of development identified for research development in Haematological-malignancies in USA (Parenteral)
- 14 Jul 2015 Amorfix Life Sciences is now called ProMIS Neurosciences